Schroder Investment Management Group’s Apellis Pharmaceuticals APLS Stock Holding History

Schroder Investment Management Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-329,134	Closed	-$8.31M	–	1188
2025 Q4	$8.31M	Buy	329,134 +156,047	+90%	+$3.66M	0.01%	666
2025 Q3	$3.92M	Sell	173,087 -312,528	-64%	-$7.29M	﹤0.01%	817
2025 Q2	$8.41M	Buy	485,615 +232,506	+92%	+$4.3M	0.01%	667
2025 Q1	$6.14M	Buy	253,109 +33,726	+15%	+$932K	0.01%	722
2024 Q4	$7M	Hold	219,383	–	–	0.01%	714
2024 Q3	$6.47M	Buy	219,383 +50,980	+30%	+$1.89M	0.01%	744
2024 Q2	$6.46M	Buy	168,403 +128,000	+317%	+$5.8M	0.01%	727
2024 Q1	$2.37M	Buy	40,403 +16,721	+71%	+$1.07M	﹤0.01%	899
2023 Q4	$1.42M	Buy	+23,682	New	+$1.2M	﹤0.01%	961

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Schroder Investment Management Group's APLS Position: Q1 2026 in Review

Schroder Investment Management Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 329,134 shares — an estimated $8.31M sold.

Schroder Investment Management Group first reported a position in APLS in Q4 2023 and held it in 9 quarters. The position peaked at $8.41M in Q2 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Schroder Investment Management Group reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Schroder Investment Management Group sold 329,134 Apellis Pharmaceuticals shares in Q1 2026, an estimated $8.31M.
Schroder Investment Management Group first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 9 quarters.
Schroder Investment Management Group's Apellis Pharmaceuticals position peaked at $8.41M in Q2 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.